Clinical Outcomes Depending on Acute Blood Pressure After Cerebral Hemorrhage

Abstract

ObjectiveTo determine the association between clinical outcomes and acute systolic blood pressure (SBP) levels achieved after intracerebral hemorrhage (ICH).MethodsEligible patients who were randomized to the ATACH‐2 (Antihypertensive Treatment in Intracerebral Hemorrhage 2) trial (ClinicalTrials.gov: NCT01176565) were divided into 5 groups by 10‐mmHg strata of average hourly minimum SBP (<120, 120–130, 130–140, 140–150, and ≥ 150 mmHg) during 2 to 24 hours after randomization. Outcomes included: 90‐day modified Rankin Scale (mRS) 4 to 6; hematoma expansion, defined as an increase ≥6 ml from baseline to 24‐hour computed tomography; and cardiorenal adverse events within 7 days.ResultsOf the 1,000 subjects in ATACH‐2, 995 with available SBP data were included in the analyses. The proportion of mRS 4 to 6 was 37.5, 36.0, 42.8, 38.6, and 38.0%, respectively. For the “140 to 150” group relative to the “120 to 130,” the odds ratio (OR), adjusting for sex, race, age, onset‐to‐randomization time, baseline National Institutes of Health Stroke Scale score, hematoma volume, and hematoma location, was 1.62 (95% confidence interval [CI], 1.02–2.58). Hematoma expansion was identified in 16.9, 13.7, 21.4, 18.5, and 26.4%, respectively. The 140 to 150 (OR, 1.80; 95% CI, 1.05–3.09) and “≥150” (1.98; 1.12–3.51) showed a higher frequency of expansion than the 120 to 130 group. Cardiorenal events occurred in 13.6, 16.6, 11.5, 8.1, and 8.2%, respectively. The 140 to 150 (0.43; 0.19–0.88) and ≥ 150 (0.44; 0.18–0.96) showed a lower frequency of the events than the 120 to 130.InterpretationBeneficial effects of lowering and maintaining SBP at 120 to 130 mmHg during the first 24 hours on clinical outcomes by suppressing hematoma expansion was somewhat offset by cardiorenal complications. ANN NEUROL 2019;85:105–113.

Intracerebral hemorrhage: an update on diagnosis and treatment

“…[101,102] combined the results of these (and other) trials, but these are of limited clinical relevance given the major differences between the INTERACT-2 and ATACH-2 trials. A subanalysis of ATACH-2 found that by lowering the blood pressure below 120-130mmHg the benefits of preventing haematoma expansion were offset by increased cardio-renal adverse events [103]. Large-scale individual patient data analyses of the INTERACT-2 and ATACH-2 trial data are awaited.…”

Clinical Features of COVID‐19 in a Young Man with Massive Cerebral Hemorrhage: Case Report

“…The vast majority of cerebral hemorrhage is manifested as small artery rupture caused by hypertension, which can cause extremely serious symptoms within a short period of time, and even affect patients' basic physiological activities such as breathing and heartbeat, resulting in death. It is a common acute cerebrovascular disease in middle-aged and elderly people, with a high fatality and disability rate [18]. The patient had no history of hypertension, sudden cerebral hemorrhage, and no vascular abnormalities such as aneurysms during the operation.…”

Acute Ischemic and Hemorrhagic Stroke and COVID-19: Case Series

“…Rupture of a small artery caused by high blood pressure can lead to death shortly due to effects of bleeding on the body's main activities, such as breathing and heart pumping. Acute cerebrovascular diseases are one of the most common diseases in middle-aged and elderly people, and with its wide range of effects, it can lead to high mortality and disability [22]. Studies have also shown that in addition to a pandemic, the coronavirus will cause a widespread stroke epidemic [23].…”